Bringing Biocatalytic Processes from Early Idea to Industrial Scale
Aminoverse enables players in the chemical industry to onboard more cost-efficient and sustainable manufacturing by delivering the right enzyme and process. With its proprietary symbiosis of wet lab work, state-of-the-art in-silico modelling, and data-driven AI, the Dutch start-up company founded in 2020 removes bottlenecks in enzyme science like long lead times or uncertain research outcomes. David Schönauer, founder and CEO of Aminoverse, shares insights into the motivation behind the company, the unique value that its enzyme services and products bring to the industry, and provides an outlook into the company’s future.
Interview with David Schönauer, Founder and CEO, Aminoverse
Continue with login
No account yet?
Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.
Register
most read
Pharma 4.0—the Key Enabler for Successful Digital Transformation in Pharma
Part 3: Seven Theses for successful Digitalization in Pharma
Lead or Lag: Europe’s AI Materials Race
How AI and Robotics are reshaping the race for materials discovery.
US Tariffs Fatal for European Pharma
Trump's tariff policy is a considerable burden and a break with previous practice.
ISPE Good Practice Guide: Validation 4.0
The Validation 4.0 Guide provides a comprehensive approach to ensuring product quality and patient safety throughout a pharmaceutical product's lifecycle.
ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance
The ECA Foundation, one of the most important not-for-profit organizations for regulatory expertise in the pharmaceutical industry, aims to become the largest independent GMP/GDP organization in the world.